Search

Search Constraints

You searched for: Author/Creator Libanati, C.

Search Results

1. Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis. Issue 1 (January 2016)

2. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Issue 12 (December 2015)

3. OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study. (15th July 2016)

4. OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results. (23rd January 2014)

5. OP0291 Romosozumab Administration is Associated with Significant Improvements in Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared with Teriparatide. (10th June 2014)

6. OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab. (12th June 2018)

8. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Issue 12 (December 2015)